Archive for Publications

Dazostinag (TAK-676) alone and in combination with pembrolizumab in patients with advanced/metastatic solid tumors: Data from phase 1 dose escalation

Phase 1/2 Trial of ASP1570, a Novel Diacylglycerol Kinase ζ Inhibitor, in Patients With Advanced Solid Tumors

Updated data from BeamionLUNG-1, a Phase Ia/b trial of the HER2-specific tyrosine kinase inhibitor, zongertinib(BI 1810631), in patients with HER2 mutation-positive NSCLC

First-in-human trial of the oral first-in-class Ubiquitin Specific Peptidase 1 (USP1) inhibitor RO7623066 (KSQ-4279), given as single agent and in combination with olaparib or carboplatin in patients with advanced solid tumors, enriched for deleterious homologous recombination repair (HRR) mutations

A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma

ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab- Paclitaxel in Patients with Advanced Solid Tumors

Preliminary Clinical Activity of RMC-6236, a First-in-Class, RAS-Selective, Tri-Complex RASMULTI(ON) Inhibitor in Patients with KRAS-Mutant Pancreatic Ductal Adenocarcinoma (PDAC) and Non-Small Cell Lung Cancer (NSCLC)

STX-478, a mutant-selective PI3Kαinhibitor clinical candidate with a best-in-class profile: Pharmacology and therapeutic activity as monotherapy and in combination in breast cancer xenograft models

BT8009-100 Phase I/II Study of Novel Bicyclic Peptide and MMAE Conjugate BT8009 in Patients with Advanced Malignancies Associated with Nectin-4 Expression

Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies

« Older Entries
Newer Entries »